Wright, I, Millikan, CH. Cerebrovascular Diseases: Transactions of the First Conference Held January 24–26, 1954 at Princeton, New Jersey. New York: Grune & Stratton, 1954.Google Scholar

Wright, I, Millikan, CH. Cerebrovascular Diseases: Second Conference. New York: Grune & Stratton, 1958.Google Scholar

NINDS Ad Hoc Committee. A classification and outline of cerebrovascular diseases. Neurology 1958;8:188–216.Google Scholar

Fisher, CM. Anticoagulant therapy in cerebral thrombosis and cerebral embolism: A national cooperative study, interim report. Neurology 1961;11:119–131.Google ScholarGoogle Scholar

Fisher, CM. Anticoagulant study. In Memoirs of a Neurologist. Rutland, VT: Sharp, 2006, vol. 3, pp. 173–235.Google Scholar

Millikan, C. Reassessment of anticoagulant therapy in various types of occlusive cerebrovascular disease. Stroke 1971;2:201–208.Google Scholar

The story of aspirin is the topic of Chapter 47 and other antiplatelets are considered in Chapter 48.Google Scholar

Vane, JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971;231:232–235.CrossRefGoogle ScholarPubMed

Fields, WS, Lemak, NA, Frankowski, RF, Hardy, RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301–314.Google Scholar

Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 1978;299:53–59.CrossRefGoogle Scholar

Barnett, Henry J. M.. Wikipedia. Available at https://en.wikipedia.org/wiki/Henry_J._M._Barnett.Google Scholar

Spence, JD, Hachinsky, V. Henry J. M. Barnett (1922–2016). Stroke 2017;48(1):2–4.Google Scholar

Van Horn, G, Grotta, JC. William S. Fields, MD, Texas medical center pioneer. Ann. Neurol. 2004;56(2):314. https://doi.org/10.1002/ana.20167.CrossRefGoogle Scholar

Fields, WS, Lemak, NA. A History of Stroke. New York: Oxford University Press, 1989.Google Scholar

Patrono, C, Ciabattoni, G, Patrignani, P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–1184.CrossRefGoogle ScholarPubMed

Wallentin, LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. JACC 1991;18:1587–1593.Google Scholar

SALT Collaborative Group. The Swedish Aspirin Low-Dose Trial. Lancet 1991;338:1345–1349.Google Scholar

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke: The Dutch TIA Trial Study Group. N. Engl. J. Med. 1991;325:1261–1266.CrossRefGoogle Scholar

Farrell, B, Godwin, J, Richards, S, Warlow, C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: Final results. J. Neurol. Neurosurg. Psychiatry 1991;54:1044–1054.CrossRefGoogle ScholarPubMed

Diener, HC, Cunha, L, Forbes, C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 1996 Nov;143(1–2):1–13.CrossRefGoogle ScholarPubMed

Hart, RG, Harrison, MJG. Aspirin wars: The optimal dose of aspirin to prevent stroke. Stroke 1996;27:585–587.Google Scholar

Peto, R, Pike, MC, Armitage, P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br. J. Cancer 1977;35:1–39.Google Scholar

Peto, R. Editorial: Aspirin and myocardial infarction. Lancet 1980;1:1172–1173.Google Scholar

Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320–331.Google Scholar

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.Google ScholarGoogle Scholar

ISIS-2 (Second international Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J. Am. Coll. Cardiol. 1988 Dec;12(6 suppl A):3A–13A.Google Scholar

The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569–1581.CrossRefGoogle Scholar

CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997 Jun 7;349(9066):1641–1649.Google Scholar

Sackett, DL, Haynes, RB, Tugwell, P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown, 1985.Google Scholar

Cochrane, A. Effectiveness and Efficiency: Random Reflections on Health Services. The Nuffield Provincial Hospital Trust, 1972.Google Scholar

Qiu, J. Charles Warlow: A career of “successive flukes.” Lancet 2008 Jun;7(6):478.Google Scholar

Djulbegovic, B, Guyatt, GH. Progress in evidence-based medicine: A quarter century on. Lancet 2017;390:415–423.Google Scholar

GRADE Working Group. The Grades of Recommendation. Assessment, Development and Evaluation Working Group. 2004.Google Scholar

The Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: Final results. Circulation 1991;84:527–539.Google Scholar

Mohr, JP, Thompson, JLP, Lazar, RM, et al. for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 2001;345:1444–1451.Google Scholar

Chimowitz, MI, Lynn, MJ, Howlett-Smith, H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 2005;352:1305–1316.CrossRefGoogle ScholarPubMed

The newer anticoagulants are discussed in Chapter 46.Google Scholar

European Investigators published the results of the European Cooperative Acute Stroke Study (ECASS). Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.Google ScholarGoogle Scholar

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995;333:1581–1587.Google Scholar

Furlan, AJ, Higashida, RT, Wechsler, L, et al. PROACT II. Intra-arterial Pro-urokinase for acute ischemic stroke: A randomized controlled trial. JAMA 1999;282;2003–2011.CrossRefGoogle ScholarPubMed

The EC-IC Bypass Study Group. Failure of the extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. N. Engl. J. Med. 1985;313:1191–1200.CrossRefGoogle Scholar

The Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomized prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke 1989;20:844–849.CrossRefGoogle Scholar

NASCET Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. 1991;325:445–453.Google ScholarGoogle Scholar

Brott, TG, Hobson, RW II, Howard, G, et al. CREST Investigators. Stenting vs endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 2010;363:11–23.Google ScholarGoogle Scholar

Halliday, A, Mansfield, A, Marro, J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomised controlled trial. Lancet 2004;363:1491–1502. Carotid artery surgery is discussed in Chapter 54 and carotid artery stenting in Chapter 55.Google Scholar

Vahedi, K, Hofmeijer, J, Juettler, E, et al. Early decompressive surgery in malignant middle cerebral artery infarction: A pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215–222.Google Scholar

Chimowitz, M, Lynn, MJ, Derdeyn, CP, et al. for the SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N. Engl. J. Med. 2011;365:993–1003.CrossRefGoogle ScholarPubMed

Turan, TN, Nizam, A, Lynn, MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 2017;88(4):379–385.Google Scholar

Mohr, JP, Parides, MK, Stapf, C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): A multicentre, non-blinded, randomised trial. Lancet 2014;383 (9917):614–621.Google Scholar

Trials that evaluated the safety and effectiveness of endovascular management of acute ischemic stroke are discussed in Chapter 56.Google Scholar

Couch, NP. About heparin, or … whatever happened to Jay McLean? J. Vasc. Surg. 1989 Jul;10(1):1–8.Google ScholarPubMed

Marcum, JA. Discovery of heparin: Contributions of William Henry Howell and Jay McLean. Physiology 1992 Oct;7(5):237–242.CrossRefGoogle Scholar

Mclean, J. The discovery of heparin. Circulation 1959 Jan;19(1):75–78.Google Scholar

McLean, J. The thromboplastic action of cephalin. Am. J. Physiol.-Leg. Content 1916 Aug 1;41(2):250–257.CrossRefGoogle Scholar

Charles, AF, Scott, DA. Studies on heparin I. The preparation of heparin. J. Biol. Chem. 1933 Oct 1;102(2):425–429.Google Scholar

Lever, R, Mulloy, B, Page, C. Heparin: A Century of Progress. Berlin: Springer Healthcare, 2012, pp. 4–18.Google Scholar

Oduah, EI, Linhardt, RJ, Sharfstein, ST. Heparin: Past, present, and future. Pharmaceuticals (Basel) 2016 Jul 4;9(3):38.Google Scholar

Caplan, L, Saver, J. Treatment. In Caplan, L (ed.), Caplan’s Stroke: A Clinical Approach, 5th ed. Cambridge: Cambridge University Press, 2016, pp. 170–177.Google Scholar

Saxena, R, Lewis, S, Berge, E, Sandercock, PA, Koudstaal, PJ. Risk of early death and recurrent stroke and effects of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333–2337.Google Scholar

Resnick, SB, Resnick, SH, Weintraub, JL, Kothary, N. Heparin in interventional radiology: A therapy in evolution. Semin. Interv. Radiol. 2005 Jun;22(2):95–107.Google Scholar

Link, KP. The discovery of dicumarol and its sequels. Circulation 1959 Jan 1;19(1):97–107.Google Scholar

Fields, WS, Lemak, NA. A History of Stroke: Its Recognition and Treatment. New York: Oxford University Press, 1989.Google Scholar

Wardrop, D, Keeling, D. The story of the discovery of heparin and warfarin. Br. J. Haematol. 2008 Jun 1;141(6):757–763.Google Scholar

Burris, RH. Karl Paul Link. In Biographical Memoirs, vol. 65. National Academies Press, 1994. Available at www.nap.edu/read/4548/chapter/9.Google Scholar

Meek, T. This month in 1939: How dead cattle led to the discovery of warfarin. PMLive. June 27, 2013. Available at www.pmlive.com/pharma_news/how_dead_cattle_led_to_the_discovery_of_warfarin_485464.Google Scholar

Wessler, S, Gitel, S. Warfarin: From bedside to bench. N. Engl. J. Med. 1984;311:645–652.Google ScholarPubMed

Deykin, D. Warfarin therapy. N. Engl. J. Med. 1970;283:691–694.CrossRefGoogle ScholarPubMed

Barritt, DW, Jordan, MB. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial. Lancet 1960;275:1309–1312.CrossRefGoogle Scholar

Ergermayer, P. Value of anticoagulants in the treatment of pulmonary embolism: A discussion paper. J. Roy. Soc. Med. 1981;74:675–681.Google Scholar

Wright, IS, Foley, WT. Use of anticoagulants in the treatment of heart disease with special reference to coronary thrombosis, rheumatic heart disease with thromboembolic complications and subacute bacterial endocarditis. Am. J. Med. 1947;3:718–739.Google Scholar

Cosgriff, SW. Prophylaxis of recurrent embolism of intracardiac origin: Protracted anticoagulant therapy on an ambulatory basis. JAMA 1950;143:870–872.Google Scholar

Szekely, P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br. Med. J. 1964:1:1209.CrossRefGoogle ScholarPubMed

McDevitt, E. Treatment of cerebral embolism. Mod. Treat. 1965;2:52.Google ScholarPubMed

Fleming, HA, Bailey, SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad. Med. J. 1971; 47:599–604.Google Scholar

Report of the working party on anticoagulant therapy in coronary thrombosis to the Medical Research Council: Assessment of short-term anticoagulant administration after cardiac infarction. Br. Med. J. 1969;1:335.Google Scholar

Kucharski, A. Medical management of political patients: The case of Dwight D. Eisenhower. Perspect. Biol. Med. 1978;22:115–126.Google Scholar

Fisher, CM. Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A National Cooperative Study, interim report. Neurology 1961;11:119–131.Google Scholar

Baker, RN, Broward, JA, Fang, HC, Fisher, CM, Groch, SN, Heyman, A. Anticoagulant therapy in cerebral infarction. Neurology 1962;12:823–835.Google Scholar

Millikan, CH, Siekert, RG, Shick, R. Studies in cerebrovascular disease, III: The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Proc. Staff Meet. Mayo Clin. 1955;30:111–126.Google Scholar

Millikan, CH, Siekert, RG, Whisnant, JP. Anticoagulant therapy in cerebrovascular disease: Current status. JAMA 1958;166:587–592.CrossRefGoogle ScholarPubMed

Whisnant, JP. Discussion. In Millikan, C, Siekert, R, Whisnant, JP (eds.), Cerebral Vascular Diseases: Third Princeton Conference on Cerebrovascular Diseases. Orlando, FL: Grune & Stratton, 1961, pp. 156–157.Google Scholar

The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 1990;323:1505–1511.CrossRefGoogle Scholar

EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255–1262.Google Scholar

The Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: Final results. Circulation 1991;84:527–539.Google Scholar

Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687–691.Google Scholar

Albers, GW. Atrial fibrillation and stroke: Three new studies, three remaining questions. Arch. Intern. Med. 1994;154:1443–1448.CrossRefGoogle ScholarPubMed

Hart, RG, Benavente, O, McBride, R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann. Intern. Med. 1999;131:492–501.CrossRefGoogle ScholarPubMed

Mohr, JP, Thompson, JLP, Lazar, RM, et al. for the Warfarin–Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 2001;345:1444–1451.CrossRefGoogle ScholarPubMed

Chimowitz, MI, Lynn, MJ, Howlett-Smith, H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 2005;352:1305–1316.Google Scholar

Koroshetz, W. Warfarin, aspirin, and intracranial vascular disease. N. Engl. J. Med. 2005;352:1368–1370.CrossRefGoogle ScholarPubMed

Bousser, MG, Ross Russell, R. Cerebral Venous Thrombosis. Philadelphia: WB Saunders, 1997.Google Scholar

Ameri, A, Bousser, MG. Cerebral venous thrombosis. Neurol. Clin. 1992;10:87–111.Google Scholar

The development of warfarin and its evolution is discussed at length in Chapter 45.Google Scholar

Rost, S, Fregin, A, Ivaskevicius, V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537–541.Google ScholarGoogle Scholar

Akins, PT, Feldman, HA, Zoble, RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation. Pooled analysis of SPORTIF III and V Clinical Trials. Stroke 2007;38:874–880.Google Scholar

Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009;361:1139–1151.Google Scholar

Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011;365:883–891.CrossRefGoogle ScholarPubMed

Granger, CB, Alexander, JH, McMurray, JJ, Lopes, RD, Hylek, EM, Hanna, M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011;365:981–992.Google Scholar

Giugliano, RP, Ruff, CT, Braunwald, E, Murphy, SA, Wiviott, SD, Halperin, JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2013;369:2093–2104.CrossRefGoogle ScholarPubMed

Eikelboom, JW, Connolly, SJ, Brueckmann, M, et al. for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013;369:1206–1214.Google Scholar

Doctrine of signatures. Science Museum.org. Available at http://broughttolife.sciencemuseum.org.uk/broughttolife/techniques/doctrine.Google Scholar

A history of aspirin. Pharmaceutical Journal. Available at www.pharmaceutical-journal.com/news-and-analysis/infographics/a-history-of-aspirin/20066661.article.Google Scholar

Stone, E. XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire. Philos. Trans. 1763 Jan 1;53:195–200.Google Scholar

Jack, DB. One hundred years of aspirin. Lancet Lond. Engl. 1997 Aug 9;350(9075):437–439.Google Scholar

Pearce, JMS. The controversial story of aspirin. World Neurology. December 2, 2014. Available at https://worldneurologyonline.com/article/controversial-story-aspirin/.Google Scholar

Buchanan, WW, Kean, WF. The treatment of acute rheumatism by salicin, by T. J. Maclagan – The Lancet, 1876. J. Rheumatol. 2002 Jun 1;29(6):1321–1323.Google Scholar

Snead, MW, Aikawa, JK. T. J. Maclagan and the treatment of rheumatic fever with salicin. AMA Arch. Intern. Med. 1958 May 1;101(5):997–1004.CrossRefGoogle Scholar

Malverde, J. How aspirin turned hero: Heroin, Bayer and Heinrich Dreser. Democratic Underground. Available at www.democraticunderground.com/11701737.Google Scholar

Lichterman, BL. Aspirin: The story of a wonder drug. BMJ 2004 Dec 11;329(7479):1408.Google Scholar

Miner, J, Hoffhines, A. The discovery of aspirin’s antithrombotic effects. Tex. Heart Inst. J. 2007;34(2):179–186.Google Scholar

Craven, LL. Coronary thrombosis can be prevented. J. Insurance Med. 1950;5:47–48.Google Scholar

Craven, LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss. Valley Med. J. 1953;75:38–44.Google ScholarPubMed

Craven, LL. Prevention of coronary and cerebral thrombosis. Miss. Valley Med. J. 1956;78:213–215.Google Scholar

Weiss, HJ, Aledort, LM, Kochwa, S. The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest. 1968;47:2169–2180.Google Scholar

Vane, JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971;231:232–235.Google Scholar

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.Google Scholar

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.Google Scholar

Bell, AD, Roussin, A, Cartier, R, Chan, WS, Douketis, JD, Gupta, A, Kraw, ME, Lindsay, TF, Love, MP, Pannu, N, Rabasa-Lhoret, R, Shuaib, A, Teal, P, Théroux, P, Turpie, AG, Welsh, RC, Tanguay, JF. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can. J. Cardiol. 2011;27:208–221.Google Scholar

Graham, I, Atar, D, Borch-Johnson, K, et al. for the ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007;194:1–45.Google Scholar

US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009;150:396–404.Google Scholar

Vandvik, PO, Lincoff, AM, Core, JM, et al. for American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e637S–e668S.Google Scholar

Mundall, J, Quintero, P, von Kaulla, K, et al. Transient monocular blindness and increased platelet aggregability treated with aspirin: A case report. Neurology 1971;21:402.Google Scholar

Harrison, MJG, Marshall, J, Meadows, JC, et al. Effect of aspirin in amaurosis fugax. Lancet 1971;2:743–744.CrossRefGoogle ScholarPubMed

Fields, WS, Lemak, N, Frankowski, R, Hardy, RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301–306.CrossRefGoogle ScholarPubMed

Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 1978;299:53–59.Google Scholar

UK-TIA Study Group. The UK-TIA Aspirin Trial: The interim results. BMJ 1988;296:316–320.Google Scholar

The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345–1349.Google Scholar

The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor stroke. N. Engl. J. Med. 1991;325:1261–1266.CrossRefGoogle Scholar

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.CrossRefGoogle Scholar

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;524:71–86.Google Scholar

Coller, BS. Historical perspective and future directions in platelet research. J. Thromb. Haemost. 2011;9(suppl 1):374–395.CrossRefGoogle ScholarPubMed

Bizzozero, G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione. L’Osservatore 1881;17:785–787.Google ScholarGoogle Scholar

Osler, W. On certain problems in the physiology of the blood corpuscles. Med. News 1886;48:421–425. The stroke contributions of Sir William Osler and his medical textbooks are discussed further in Chapter 14.Google Scholar

Gustav Victor Rudolf Born. Wikipedia. Available at https://en.wikipedia.org/wiki/Gustav_Victor_Rudolf_Born.Google Scholar

Born, GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.Google ScholarGoogle Scholar

Brownlee, C. Biography of Barry S. Coller. Proc. Natl. Acad. Sci. U.S.A 2004 Sep 7;101(36):13111–13113.Google Scholar

The history and evolution of the antiplatelet introduction of aspirin by Bayer is discussed in detail in Chapter 46.Google Scholar

Personal communication from Wolfgang Eisert, who directed dipyridamole research at Boehringer-Ingelheim.Google Scholar

Eisert, W, Gruber, P. Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation. US Patent 6015577A. https://patents.google.com/patent/US6015577A/en.Google Scholar

Sullivan, J, Harken, D, Gorlin, R. Pharmacologic control of thromboembolic complications of aortic valve replacement. N. Engl. J. Med. 1971;284:1391–1394.Google Scholar

Fields, WS, Yatsu, F, Conomy, J, et al. Persantine-aspirin trial in cerebral ischemia: The American-Canadian Cooperative Study group. Stroke 1983;14:97–103.Google ScholarGoogle Scholar

ESPS Group. European Stroke Prevention Study (ESPS): Principal endpoints. Lancet 1987; 2:1351–1354.Google ScholarGoogle Scholar

The ESPRIT Study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial. Lancet 2006;367:1665–1673.Google Scholar

Verro, P, Gorelick, PB, Nguyen, D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: A meta-analysis. Stroke 2008;39(4):1358–1363.Google Scholar

Ikeda, Y, Kikuchi, M, Murakami, H. Comparison of the inhibitory effects of cilostazole, acetylsalicylic acid, and ticlopidine on platelet function ex vivo: Randomized, double-blind cross-over study. Drug Res. 1987;37:563–566.Google ScholarGoogle Scholar

Gotoh, F, Tohgi, H, Hirai, S, et al. Cilostazole stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 2000;9:147–157.Google Scholar

Kwon, SU, Cho, Y-J, Koo, J-S, et al. Cilostazole prevents the progression of the symptomatic intracranial stenosis: The multicenter double-blind placebo-controlled trial of cilostazole in symptomatic intracranial arterial stenosis. Stroke 2005;36:782–786.Google Scholar

Quinn, MJ, Fitzgerald, DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667–1672.Google ScholarGoogle Scholar

Hass, WK, Easton, JD, Adams, HP Jr, Pryse-Phillips, W, Molony, BA, Anderson, S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke study group. N. Engl. J. Med. 1989;321:501–507.Google ScholarGoogle Scholar

Maffrand, JP. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? C. R. Chim. 2012;15(8):737–743.Google Scholar

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet 1996;348:1329–1339.Google Scholar

Diener, HC, Bogousslavsky, J, Brass, LM, Cimminiello, C, Csiba, L, Kaste, M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.Google ScholarGoogle Scholar

Bhatt, DL, Fox, KA, Hacke, W, Berger, PB, Black, HR, Boden, WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 2006;354:1706–1717.Google Scholar

Wang, Y, Wang, Y, Zhao, X, et al. and Johnston SC for the CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N. Engl. J. Med. 2013;369:1–13.Google Scholar

Johnston, SC, Easton, JD, Farrant, M, et al. for the Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N. Engl. J. Med. 2018;379:215–225.Google Scholar

Johnston, SC, Amarenco, P, Albers, GW, et al. for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N. Engl. J. Med. 2016;375:35–43.CrossRefGoogle ScholarPubMed

Johnston, SC, Amarenco, P, Denison, H, et al. for the THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N. Engl. J. Med. 2020;383:207–217.Google Scholar

Coller, BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb. Haemost. 2001;86(1):427–443.Google Scholar

Lefkovits, J, Plow, EF, Topol, EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995;332:1553–1559.CrossRefGoogle ScholarPubMed

Adams, HP Jr, Effron, MB, Torner, J, Davalos, A, Frayne, J, Teal, P, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (AbESTT-II). Stroke 2008;39:87–99.Google Scholar

Topol, EJ, Easton, D, Harrington, RA, Amarenco, P, Califf, RM, Graffagnino, C, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406.Google Scholar

Caplan, LR. Vertebrobasilar Ischemia and Hemorrhage: Clinical Findings, Diagnosis, and Management of Posterior Circulation Disease. Cambridge: Cambridge University Press, 2014, pp. 215–216.Google Scholar

O’Rourke, MF. Frederic Akbar Mahomed. Hypertension 1992;19:212–217.Google ScholarGoogle Scholar

Samuel Siegfried Karl von Basch (1837–1905). Nature 1937;140:393–394.Google Scholar

Bruenn, HG. Clinical notes on the illness and death of president Franklin D. Roosevelt. Ann. Intern. Med. 1970;72:579–591.Google Scholar

Smithwick, R. H. Hypertensive cardiovascular disease: Effect of thoracolumbar splanchnicectomy on mortality and survival rates. JAMA 1951;147:1611–1615.Google Scholar

Saklayen, MG, Deshpande, N. Timeline of history of hypertension treatment. Front. Cardiovasc. Med. 2016;3:3. doi: 10.3389/fcvm.2016.00003.Google ScholarGoogle Scholar

Guyton, AC. Blood pressure control: Special role of kidneys and body fluid. Science 1991;252:1813–1816.Google Scholar

Freis, ED, Wanko, A, Wilson, IM, Parrish, AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. JAMA 1958;166:137–140.Google Scholar

Black, James W.. Lindau Nobel Laureate Meetings. Available at www.mediatheque.lindau-nobel.org/laureates/black.Google Scholar

Castle, WB. George Richards Minot. Biographical Memoirs of the National Academy of Sciences 1974;45:337–383.Google Scholar

Obituary. Joslin, Elliott P.. Br. Med. J. 1962;1:729.Google Scholar

Joslin, EP. The prevention of diabetes mellitus. JAMA 1921;76(2):79–84.Google Scholar

Rosenfeld, L. Insulin: Discovery and controversy. Clin. Chem. 2002;48:2270–2288.Google ScholarGoogle Scholar

White, JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27(2):82–86.Google Scholar

Reaven, G. Syndrome X, a short history. Ochsner J. 2001;3(3):124–125.Google ScholarGoogle ScholarGoogle Scholar

Kannel, WB, Dawber, TR, Friedman, GD, Glennon, WE, McNamara, PM. Risk factors in coronary heart disease: An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham Study. Ann. Intern. Med. 1964;61:888–899.Google Scholar

Golding, SS, Allen, NB. Cholesterol and atherosclerotic cardiovascular disease: A lifelong problem. J. Am. Heart Assoc. 2019;8(11):e012924.Google Scholar

Duncan, MS, Vasan, RS, Xanthakis, V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all‐cause mortality: Observations from the Framingham Study over 35 years. J. Am. Heart Assoc. 2019;8:e011433.Google Scholar

Goldstein, Joseph L., biographical. The Nobel Prize. Available at www.nobelprize.org/prizes/medicine/1985/goldstein/biographical/.Google Scholar

Goldstein, JL, Brown, MS. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009;29(4):431–438.Google Scholar

Brown, Michael S., biographical. The Nobel Prize. Available at www.nobelprize.org/prizes/medicine/1985/brown/biographical/.Google Scholar

Endo, A. A historical perspective on the discovery of statins. Proc. Japan Academy Ser. B Phys. Biol. Sci. 2010;86(5):484–493.Google ScholarGoogle ScholarGoogle Scholar

Amarenco, P, Goldstein, LB, Szarek, M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198–3204.Google ScholarGoogle Scholar

Karatasakis, A, Danek, B, Karacsonyi, J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J. Am. Heart Assoc. 2017;6(12):e006910. doi: 10.1161/JAHA.117.006910.Google ScholarGoogle Scholar

Banach, M, Duell, PB, Gotto, AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020 Jul 1. doi: 10.1001/jamacardio.2020.2314 (Epub ahead of print).Google Scholar

Breathnach, CS, Moynihan, JB. Intensive care 1650: The revival of Anne Greene (c. 1628–59). J. Med. Biogr. 2009;17:35–38.Google Scholar

Drake, CG, Barr, HW, Coles, JC, Gergely, NF. The use of extracorporeal circulation and profound hypothermia in the treatment of ruptured intracranial aneurysm. J. Neurosurg. 1964;21:575–581.Google ScholarGoogle Scholar

Bernard, SA, Gray, TW, Buist, MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N. Engl. J. Med. 2002;346:557–563.Google ScholarGoogle Scholar

van der Worp, HB, de Haan, P, Morrema, E, Kalkman, CJ. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J. Neurol. 2005;252:1108–1114.Google Scholar

Spielmeyer, W. Zur pathogenese örtlich elektiver grehirnveränderungen. Zeitschrift für die gesamte Neurologie und Psychiatrie 1925;99:756–776.Google Scholar

Pulsinelli, WA, Brierley, JB, Plum, F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann. Neurol. 1982;11:491–498.Google Scholar

Diemer, NH, Jorgensen, MB, Johansen, FF, Sheardown, M, Honore, T. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta Neurol. Scand. 1992;86:45–49.Google ScholarGoogle Scholar

Ito, U, Spatz, M, Walker, JT Jr, Klatzo, I. Experimental cerebral ischemia in Mongolian gerbils. I. Light microscopic observations. Acta Neuropathol. 1975;32:209–223.Google ScholarGoogle Scholar

Petito, CK, Feldmann, E, Pulsinelli, WA, Plum, F. Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology 1987;37:1281–1286.Google Scholar

Paulson, OB, Hossman, K-A, Ingvar, M, Sokoloff, L. In memoriam: Bo K. Siesjö, 1930–2013. J. Cereb. Blood Flow Metab. 2014;34(1):1.Google ScholarGoogle Scholar

Posner, JB. Fred Plum, MD (1924–2010). Arch. Neurol. 2010;67(11):1409–1410.Google Scholar

Branston, NM, Symon, L, Crockard, HA, Pasztor, E. Relationship between the cortical evoked potential and local cortical blood flow following acute middle cerebral artery occlusion in the baboon. Exp. Neurol. 1974;45:195–208.Google ScholarGoogle Scholar

Symon, LN, Branston, M, Strong, AJ, Hope, TD. The concepts of thresholds of ischaemia in relation to brain structure and function. J. Clin. Pathol. Suppl. (R. Coll. Pathol.) 1977;11:149–154.Google Scholar

Baron, JC. Mapping the ischaemic penumbra with PET: Implications for acute stroke treatment. Cerebrovasc. Dis. 1999;9:193–201.Google ScholarGoogle ScholarGoogle Scholar

Ginsberg, MD, Busto, R. Rodent models of cerebral ischemia. Stroke 1989;20:1627–1642.Google ScholarGoogle Scholar

Brown, AW, Brierley, JB. The earliest alterations in rat neurones and astrocytes after anoxia-ischaemia. Acta Neuropathol. 1973;23:9–22.Google ScholarGoogle Scholar

Abe, K, Aoki, M, Kawagoe, J, et al. Ischemic delayed neuronal death: A mitochondrial hypothesis. Stroke 1995;26:1478–1489.Google Scholar

Dirnagl, U, Simon, RP, Hallenbeck, JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248–254.Google ScholarGoogle Scholar

Chamorro, A, Lo, EH, Renù, A, van Leyden, K, Lyden, P. The future of neuroprotection in stroke. J. Neurol. Neurosurg. Psychiatry 2021;92(2):129–135.Google Scholar

Krams, MK, Lees, R, Hacke, W, Grieve, AP, Orgogozo, JM, Ford, GA, and ASTIN study investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003;34:2543–2548.Google Scholar

Hall, CN, Reynell, C, Gesslein, B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014;508:55–60.Google Scholar

Rothman, SM, Olney, JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 1986;19:105–111.Google Scholar

Choi, DW, Rothman, SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 1990;13:171–182.Google Scholar

Simon, RP, Swan, JH, Griffiths, T, Meldrum, BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984;226:850–852.Google Scholar

Gill, R, Foster, AC, Woodruff, GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 1987;7:3343–3349.Google Scholar

Buchan, A, Pulsinelli, WA. Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci. 1990;10:311–316.CrossRefGoogle Scholar

Nellgard, B, Wieloch, T. Cerebral protection by AMPA- and NMDA-receptor antagonists administered after severe insulin-induced hypoglycemia. Exp. Brain Res. 1992;92:259–266.Google Scholar

Takizawa, S, Hogan, M, Hakim, AM. The effects of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischemia. J. Cereb. Blood Flow Metab. 1991;11:786–793.Google ScholarGoogle Scholar

Sheardown, MJ, Suzdak, PD, Nordholm, L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur. J. Pharmacol. 1993;236:347–353.Google ScholarGoogle Scholar

Siesjo, BK, Agardh, CD, Bengtsson, F. Free radicals and brain damage. Cerebrovasc. Brain Metab. Rev. 1989;1:165–211.Google Scholar

Lees, KR, Zivin, JA, Ashwood, T, et al. for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 2006;354:588–600.Google Scholar

Shuaib, A, Lees, KR, Lyden, P et al., and Saint Il Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007;357:562–571.Google Scholar

Belayev, L, Liu, Y, Zhao, W, Busto, R, Ginsberg, MD. Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553–560.Google Scholar

Martin, RH, Yeatts, SD, Hill, MD, et al. and ALIAS Parts 1 and 2 and Nett Investigators. ALIAS (Albumin in Acute Ischemic Stroke) trials: Analysis of the combined data from parts 1 and 2. Stroke 2016;47:2355–2359.Google Scholar

Shuaib, A, Bornstein, NM, Diener, HC, et al. and Sentis trial investigators. Partial aortic occlusion for cerebral perfusion augmentation: Safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke 2011;42:1680–1690.Google Scholar

Fisher, M, Feuerstein, G, Howells, DW, et al. STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40(6):2244–2250.Google Scholar

Hill, MD, Goyal, M, Menon, BK, et al. and Escape-Na Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): A multicentre, double-blind, randomised controlled trial. Lancet 2020;395:878–887.Google Scholar

Hill, MD, Martin, RH, Mikulis, D, et al. and ENACT trial investigators. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942–950.Google Scholar

Karnatovskaia, LV, Wartenberg, KE, Freeman, WD. Therapeutic hypothermia for neuroprotection: History, mechanisms, risks, and clinical applications. Neurohospitalist 2014;4:153–163.Google Scholar

Bigelow, WG, Lindsay, WK, Greenwood, WF. Hypothermia, its possible role in cardiac surgery: An investigation of factors governing survival in dogs at low body temperatures. Ann. Surg. 1950;132:849–866.Google Scholar

van der Worp, HB, Sena, ES, Donnan, GA, Howells, DW, Macleod, MR. Hypothermia in animal models of acute ischaemic stroke: A systematic review and meta-analysis. Brain 2007;130:3063–3074.Google Scholar

De Georgia, MA, Krieger, DW, Abou-Chebl, A, et al. Cooling for Acute Ischemic Brain Damage (COOL AID): A feasibility trial of endovascular cooling. Neurology 2004;63:312–317.Google Scholar

Hemmen, TM, Raman, R, Guluma, KZ, et al. and ICTuS-L Investigators. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): Final results. Stroke 2010;41:2265–2270.Google Scholar

Horn, CM, Sun, CH, Nogueira, RG, et al. Endovascular Reperfusion and Cooling in Cerebral Acute Ischemia (ReCCLAIM I). J. Neurointerv. Surg. 2014;6:91–95.Google Scholar

Lyden, P, Hemmen, T, Grotta, J, et al. and collaborators. Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 2016;47:2888–2895.Google Scholar

van der Worp, HB, Macleod, MR, Bath, PMW, et al. and the EuroHYP-1 Investigators. Therapeutic hypothermia for acute ischaemic stroke: Results of a European multicentre, randomised, phase III clinical trial. Eur. Stroke J. 2019;4:254–262.Google Scholar

Lougheed, WM, Kahn, DS. Circumvention of anoxia during arrest of cerebral circulation for intracranial surgery. J. Neurosurg. 1955;12:226–239.Google Scholar

Schwartz, AE, Stone, JG, Finck, AD, et al. Isolated cerebral hypothermia by single carotid artery perfusion of extracorporeally cooled blood in baboons. Neurosurgery 1996;39:577–581; discussion 81–82.Google Scholar

The early history of thrombolysis, streptokinase, and tPA is discussed in Maroo, A, Topol, EJ. The early history and development of thrombolysis in acute myocardial infarction. J. Thromb. Haemostasis 2004;2:1867–1870.Google ScholarGoogle ScholarGoogle ScholarGoogle Scholar

Zivin, JA, Simmons, JG. tPA for Stroke: The Story of a Controversial Drug. New York: Oxford University Press, 2011.Google Scholar

Bryan, TPJ. The rise and fall of the clot buster: A review on the history of streptokinase. Pharm. J. 2014. Available at www.pharmaceutical-journal.com/news-and-analysis/features/the-rise-and-fall-of-the-clot-buster-a-review-on-the-history-of-streptokinase/20065679.article.Google Scholar

Sherry, S. The origin of thrombolytic therapy. J. Am. Coll. Cardiol. 1989 Oct 1;14(4):1085–1092.Google Scholar

DeWood, MA, Spores, J, Notske, R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 1980;303:897–902.Google Scholar

Meyer, JS, Gilroy, J, Barnhart, MI, Johnson, JF. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963;13:927–937.Google ScholarGoogle ScholarGoogle Scholar

Donnan, GA, Davis, SM, Chambers, BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276(12):961–966.Google Scholar

Multicenter Acute Stroke Trial-Europe Study Group: Hommel, M, Cornu, C, Boutitie, F, Boissel, JP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 1996;335(3):145–150.Google Scholar

Fletcher, AP, Alkjersig, N, Lewis, M, Tulevski, V, Davies, A, Brooks, JE, Hardin, WB, Landau, WM, Raichle, ME. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135–142.Google Scholar

Collen, Desiree. Wikipedia. Available at https://en.wikipedia.org/wiki/D%C3%A9sir%C3%A9_Collen.Google Scholar

Collen, D, Lijnen, HR. Tissue-type plasminogen activator: A historical perspective and personal account. J. Thromb. Haemostasis 2004;2(4):541–546.Google Scholar

Van de Werf, F, Ludbrook, PA, Bergmann, SR, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med. 1984;310:609–613.Google ScholarGoogle Scholar

The early investigations of thrombolytic therapy are reviewed in del Zoppo, GJ, Poeck, K, Pessin, MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 1992;32:78–86.Google ScholarGoogle ScholarGoogle Scholar

Brott, T, Haley, EC, Levy, DE, et al. Urgent therapy for stroke: Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632–640.Google ScholarGoogle Scholar

Levy, DE, Brott, TG, Haley, EC, et al. Factors related to intracranial hematoma formation in patients receiving t-PA for acute, ischemic stroke. Stroke 1994;25:291–297.Google Scholar

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995;333:1581–1587.Google Scholar

Kwatkowski, TG, Libman, RB, Frankel, M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N. Engl. J. Med. 1999;340(23):1781–1787.Google Scholar

Brott, T, Adams, HP Jr, Olinger, CP, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989;20(7):864–870.Google ScholarGoogle Scholar

The European Investigators published the results of the European Cooperative Acute Stroke Study (ECASS). Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.Google ScholarGoogle ScholarGoogle Scholar

Toni, D, Lorenzano, S, Puca, E, Prencipe, M. The SITS-MOST registry. Neurol. Sci. 2006;27(suppl 3):S260–S262.Google ScholarGoogle Scholar

Caplan, LR, Mohr, JP, Kistler, JP, Koroshetz, W. Thrombolysis: Not a panacea for ischemic stroke. N. Engl. J. Med. 1997;337:1309–1310, 1313.Google ScholarGoogle Scholar

Bhatia, R, Hill, MD, Shobha, N, Menon, B, Bal, S, Kochar, P, Watson, T, Goyal, M, Demchuk, AM. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action. Stroke 2010;41:2254–2258.Google Scholar

Thomalla, G, Simonsen, CZ, Boutitie, F, et al. WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N. Engl. J. Med. 2018;379(7):611–622.Google ScholarGoogle Scholar

Nogueira, RG, Jadhay, AP, Hausen, DG, et al. for the DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N. Engl. J. Med. 2018;378:11–21.Google ScholarGoogle Scholar

Van de Werf, F, Cannon, CP, Luyten, A, et al. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: The ASSENT-1 trial. Am. Heart J. 1999;137:786–791.Google ScholarGoogle Scholar

Huang, X, MacIsaac, R, Thompson, JL, Levin, B, Buchsbaum, R, Haley, EC, et al. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials. Int. J. Stroke 2016 11:534–543.Google ScholarGoogle ScholarGoogle Scholar

Hacke, W, Zeumer, H, Ferbert, A, Bruckman, H. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1998;29:1216–1222.Google Scholar

del Zoppo, GJ, Higashida, RT, Furlan, AJ, et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4–11.Google Scholar

Furlan, AJ, Higashida, RT, Wechsler, L, et al. PROACT II. Intra-arterial pro-urokinase for acute ischemic stroke: A randomized controlled trial. JAMA 1999;282;2003–2011.Google Scholar

Furlan, AJ, Higashida, R, Katzan, I, Abou-Chebl, A, Russman, A. Intra-arterial thrombolysis in acute ischemic stroke. In Lyden, PD (ed.), Thrombolytic Therapy for Acute Stroke, 2nd ed. Totowa, NJ: Humana Press, 2005, pp. 159–184.Google Scholar

Lindberg, PJ, Mattle, HP. Therapy of basilar artery occlusion: A systematic analysis comparing intra-aerterial and intravenous thrombolysis. Stroke 2006;37:922–928.Google ScholarGoogle Scholar

Ribes, MF. Des recherches faites sur la phlebite. In Revue Médicale Francaise et Etrangere et Journal de Clinique de l’Hotel-Dieu et de la Charité de Paris. 1825, vol. 3, pp. 5–41.Google Scholar

Plarr’s Lives of the Fellows. Frederick Ross Stansfield. The Royal College of Surgeons of England. Available at https://livesonline.rcseng.ac.uk/client/en_GB/lives/search/detailnonmodal/ent:$002f$002fSD_ASSET$002f0$002fSD_ASSET:379868/one.Google Scholar

Stansfield, FR. Puerperal cerebral thrombophlebitis treated by heparin. Br. Med. J. 1942;1(4239):436–438.Google Scholar

Ronald Arthur Jones. Royal College of Physicians. Available at https://history.rcplondon.ac.uk/inspiring-physicians/ronald-arthur-jones.Google Scholar

Crafoord, C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir. Scand. 1937(79):407–426.Google Scholar

Van Creveld, S, De Bruyne, JI, Stronk, MG. [Thrombosis of the superior sinus longitudinalis in an infant treated with heparin and intravenous fluid supply]. Ned. Tijdschr. Geneeskd. 1949;93(15):1144–1148.Google Scholar

Holub, K. [Intracranial venous thrombosis and thrombophlebitis]. Wien Klin. Wochenschr. 1953;65(26):540–541.Google Scholar

Cairns, DR, Melton, G. Thrombosis of cerebral veins in the puerperium. Br. Med. J. 1942;1(4239):439.Google Scholar

Ehrenmitgliedschaft Prof. Dr. Karl Max Einhäupl. Charite – Universitätsmedizin Berlin. Available at https://alumni.charite.de/start_unterseiten/prof_dr_k_m_einhaeupl_ehrenmitglied/.Google Scholar

Einhäupl, KM, Villringer, A, Meister, W, Mehraein, S, Garner, C, Pellkofer, M, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338(8767):597–600.Google Scholar

Stam, J, Lensing, AWA, Vermeulen, M, Tijssen, JGP. Heparin treatment for cerebral venous and sinus thrombosis. Lancet 1991;338(8775):1154.Google Scholar

Vermeulen, M, Stam, J, Hijdra, A, van Gijn, J. In memoriam Prof. Dr. H. van Crevel. August 26, 2002. Available at www.ntvg.nl/artikelen/memoriam-profdrhvan-crevel/volledig.Google Scholar

Based on an interview with Prof. dr. Jan Stam.Google Scholar

de Bruijn, SF, Stam, J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30(3):484–488.Google Scholar

Coutinho, JM, Stam, J. How to treat cerebral venous and sinus thrombosis. J. Thromb. Haemost. 2010;8(5):877–883.Google Scholar

Stam, J, De Bruijn, SF, DeVeber, G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002(4):Cd002005.Google ScholarGoogle ScholarGoogle Scholar

Bousser, MG. Cerebral venous thrombosis: Nothing, heparin, or local thrombolysis? Stroke 1999;30(3):481–483.Google Scholar

Bousser, MG, Eschwege, E, Haguenau, M. Aspirin and stroke prevention. Lancet 1988;1(8578):179.Google Scholar

Cabut, S. Marie-Germaine Bousser, reine de la neurologie. Le Monde, January 3, 2013. Available at www.lemonde.fr/sciences/article/2013/01/03/marie-germaine-bousser-reine-de-la-neurologie_1812632_1650684.html.Google Scholar

The Brain Prize: Marie-Germaine Bousser. Lundbeckfonden. Available at https://lundbeckfonden.com/marie-germaine-bousser. The education and career of Dr. Bousser is also included in Chapter 21.Google Scholar

Ferro, JM, Canhão, P, Stam, J, Bousser, MG, Barinagarrementeria, F. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35(3):664–670.Google Scholar

Einhäupl, K, Stam, J, Bousser, MG, De Bruijn, SF, Ferro, JM, Martinelli, I, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur. J. Neurol. 2010;17(10):1229–1235.Google Scholar

The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N. Engl. J. Med. 1997;337(10):657–662.Google ScholarGoogle Scholar

Coutinho, JM, Seelig, R, Bousser, MG, Canhão, P, Ferro, JM, Stam, J. Treatment variations in cerebral venous thrombosis: An international survey. Cerebrovasc. Dis. 2011;32(3):298–300.Google Scholar

Vines, FS, Davis, DO. Clinical-radiological correlation in cerebral venous occlusive disease. Radiology 1971;98(1):9–22.Google Scholar

Di Rocco, C, Iannelli, A, Leone, G, Moschini, M, Valori, VM. Heparin-urokinase treatment in aseptic dural sinus thrombosis. Arch. Neurol. 1981;38(7):431–435.Google Scholar

Scott, JA, Pascuzzi, RM, Hall, PV, Becker, GJ. Treatment of dural sinus thrombosis with local urokinase infusion: Case report. J. Neurosurg. 1988;68(2):284–287.Google Scholar

Kim, SY, Suh, JH. Direct endovascular thrombolytic therapy for dural sinus thrombosis: Infusion of alteplase. AJNR Am. J. Neuroradiol. 1997;18(4):639–645.Google Scholar

Caso, V, Billeci, AM, Leys, D. Interventional neuroradiology in the treatment of cerebral venous thrombosis. Front. Neurol. Neurosci. 2008;23:144–160.Google Scholar

Coutinho, JM, van den Berg, R, Zuurbier, SM, Majoie, CB, Stam, J. Mechanical thrombectomy cannot be considered as first-line treatment for cerebral venous thrombosis. J. Neurointerv. Surg. 2013;5(6):621–622.Google Scholar

Stam, J, Majoie, CB, van Delden, OM, van Lienden, KP, Reekers, JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: A prospective study. Stroke 2008;39(5):1487–1490.Google Scholar

Coutinho, JM, Zuurbier, SM, Bousser, MG, Ji, X, Canhão, P, Roos, YB, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: The TO-ACT randomized clinical trial. JAMA Neurol. 2020;77(8):966–973.Google Scholar

Canhão, P, Ferro, JM, Lindgren, AG, Bousser, MG, Stam, J, Barinagarrementeria, F. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005;36(8):1720–1725.Google Scholar

Ferro, JM, Bousser, M-G, Canhão, P, Coutinho, JM, Crassard, I, Dentali, F, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – Endorsed by the European Academy of Neurology. European J. Neurol. 2017;24(10):1203–1213.Google Scholar

Milandre, L, Gueriot, C, Girard, N, Ali Cherif, A, Khalil, R. [Cerebral venous thrombosis in adults. Diagnostic and therapeutic aspects in 20 cases]. Ann. Med. Interne (Paris) 1989;139(8):544–554.Google Scholar

Riva, N, Carrier, M, Gatt, A, Ageno, W. Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. Res. Pract. Thromb. Haemost. 2020;4(7):1192–1202.Google Scholar

Ferro, JM, Coutinho, JM, Dentali, F, Kobayashi, A, Alasheev, A, Canhão, P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: A randomized clinical trial. JAMA Neurol. 2019;76(12):1457–1465.Google Scholar

Lurkin, A, Derex, L, Fambrini, A, Bertoletti, L, Epinat, M, Mismetti, P, et al. Direct oral anticoagulants for the treatment of cerebral venous thrombosis. Cerebrovasc. Dis. 2019;48(1–2):32–37.Google Scholar

Lanska, DJ. The historical origins of stroke rehabilitation. In Stein, J, Harvey, RL, Macko, RF, Winstein, CJ, Zorowitz, RD (eds.), Stroke Recovery and Rehabilitation. New York: Demos Medical Publishing, 2009, pp. 3–30.Google Scholar

Rusk, HA. A World to Care For: The Autobiography of Howard A. Rusk, M.D. Random House, 1972.Google Scholar

Taub, E. Foreword for neuroplasticity and neurorehabilitation. Front. Hum. Neurosci. 2014 Jul 24;8. Available at www.ncbi.nlm.nih.gov/pmc/articles/PMC4109562/.Google Scholar

Doidge, N. The Brain That Changes Itself: Stories of Personal Triumph from the Frontiers of Brain Science. Penguin UK, 2008.Google Scholar

Taub, Edward. Wikipedia. Available at https://en.wikipedia.org/w/index.php?title=Edward_Taub&oldid=85886212.Google Scholar

Over the Horizon. The Brain That Changes Itself – Full documentary. YouTube. May 26, 2013. Available at www.youtube.com/watch?v=bFCOm1P_cQQ.Google Scholar

Taub, E, Uswatte, G. Constraint-induced movement therapy: Bridging from the primate laboratory to the stroke rehabilitation laboratory. J. Rehabil. Med. 2003 May;(41 Suppl):34–40.Google Scholar

Kwakkel, G, Veerbeek, JM, van Wegen, EEH, Wolf, SL. Constraint-induced movement therapy after stroke. Lancet Neurol. 2015 Feb;14(2):224–234.Google ScholarGoogle ScholarGoogle Scholar

Silver Spring monkeys. Wikipedia. Available at https://en.wikipedia.org/w/index.php?title=Silver_Spring_monkeys&oldid=880337663.Google Scholar

Unnecessary Fuss. Wikipedia. Available at https://en.wikipedia.org/wiki/Unnecessary_Fuss.Google Scholar

Claflin, ES, Krishnan, C, Khot, SP. Emerging treatments for motor rehabilitation after stroke. Neurohospitalist 2015 Apr;5(2):77–88.Google Scholar

Boonzaier, J, van Tilborg, GAF, Neggers, SFW, Dijkhuizen, RM. Noninvasive brain stimulation to enhance functional recovery after stroke: Studies in animal models. Neurorehabil. Neural Repair 2018 Nov;32(11):927–940.Google Scholar

Gallese, V, Fadiga, L, Fogassi, L, Rizzolatti, G. Action recognition in the premotor cortex. Brain 1996;119(2):593–609.Google Scholar

Ramachandran, VS, Altschuler, EL. The use of visual feedback, in particular mirror visual feedback, in restoring brain function. Brain 2009 Jul 1;132(7):1693–1710.Google Scholar

Tosi, G, Romano, D, Maravita, A. Mirror box training in hemiplegic stroke patients affects body representation. Front. Hum. Neurosci. 2018 Jan 4;11. Available at www.ncbi.nlm.nih.gov/pmc/articles/PMC5758498/.Google Scholar

Norton, A, Zipse, L, Marchina, S, Schlaug, G. Melodic intonation therapy: Shared insights on how it is done and why it might help. Ann. N Y Acad. Sci. 2009 Jul;1169:431–436.Google Scholar

Tamplin, J, Baker, FA, Jones, B, Way, A, Lee, S. “Stroke a Chord”: The effect of singing in a community choir on mood and social engagement for people living with aphasia following a stroke. NeuroRehabilitation 2013;32. Available at https://pubmed.ncbi.nlm.nih.gov/23867418/.Google Scholar

Cramer, SC, Caplan, LR. Recovery, rehabilitation and repair. In Caplan, L (ed.), Caplan’s Stroke: A Clinical Approach, 5th ed. New York: Cambridge University Press, 2016, pp. 608–626.Google Scholar

Kondziolka, D, Steinberg, GK, Wechsler, L, Meltzer, CC, Elder, E, Gebel, J, et al. Neurotransplantation for patients with subcortical motor stroke: A phase 2 randomized trial. J. Neurosurg. 2005;103:38–45.Google ScholarGoogle ScholarGoogle Scholar

Fisher, CM. Occlusion of the internal carotid artery. AMA Arch. Neurol. Psychiatry 1951;65:346–377.Google Scholar

Pearce, JMS. Historical note on carotid disease and ligation. Eur. Neurol. 2014;72:26–29.Google Scholar

Cooper, A. Account of the first successful operation performed on the common carotid artery for aneurysm in the year 1808, with post-mortem examination in 1821. Guy’s Hosp. Rep. 1836;1:53–59.Google Scholar

Chiari, H. Uber das Verhalten des Tielungswinkels der Carotis communis bei der Endarteritis chronica deformans. Verhandl. deutschpath. Gesellsch. 1905;9:326–330. Chapter 15 includes more information about Hans Chiari and his work.Google Scholar

The work of Moniz and the later evolution of cerebral angiography is discussed in detail in Chapter 31.Google Scholar

Seldinger, SI. Catheter replacement of the needle in percutaneous arteriography. Acta Radiol. 1953;39:368–376.Google Scholar

Chao, WH, Kwan, ST, Lyman, RS, et al. Thrombosis of the left internal carotid artery. Arch. Surg. 1938:37:100–111.Google Scholar

Conley, J, Pack, G. Surgical procedure for lessening the hazard of carotid bulb excision. Surgery 1952;31:845–858.Google Scholar

Fisher, CM. Occlusion of the carotid arteries: Further experiences. AMA Arch. Neurol. Psychiatry 1954;72;187–204.Google ScholarGoogle Scholar

Carrea, R, Molins, M, Murphy, G. Surgical treatment of spontaneous thrombosis of the internal carotid artery in the neck: Carotid carotideal anastomosis. Acta Neurol. Latinoamer. 1955;1:71–78.Google Scholar

Eastcott, H, Pickering, G, Rob, C. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. Lancet 1954;267(2):994–996.Google ScholarGoogle Scholar

Dos Santos, JC. From embolectomy to endarterectomy or the fall of a myth. J. Cardiovasc. Surg. 1976;17:113–128.Google Scholar

Strully, KJ, Hurwitt, ES, Blankenberg, HW. Thromboendarterectomy for thrombosis of the internal carotid artery in the neck. J. Neurosurg. 1953;10:474–482.Google Scholar

DeBakey, M. Successful carotid endarterectomy for cerebrovascular insufficiency: Nineteen-year follow-up. JAMA 1975;233:1083–1085.Google Scholar

Cooley, D, Al-Naaman, Y, Carton, C. Surgical treatment of arteriosclerotic occlusion of common carotid artery. J. Neurosurg. 1956;13:500–506.Google Scholar

Bahnson, H, Spencer, F, Quattlebaum, JJ. Surgical treatment of occlusive disease of the carotid artery. Ann. Surg. 1959;149:711–720.Google Scholar

Fields, WS, Maslenikov, V, Meyer, JS, et al. Joint Study of Extracranial Artery Occlusion: V. Progress report of prognosis following surgery or non- surgery treatment for transient ischemic attacks and cervical carotid artery lesions. JAMA 1970;211:1993–2003.Google Scholar

National Center for Health Statistics. Detailed Diagnosis and Procedures, National Hospital Discharge Survey. Vital and Health Statistics. Series 13. Washington, DC: Government Printing Office, 1992–1997.Google Scholar

Barnett, HJM, Plum, F, Walton, JN. An expression of concern. Stroke 1984;15(6):942–943.Google Scholar

Spence, JD, Hachinski, V. In memoriam. Henry J. M. Barnett, 1922–2016. Stroke 2017;48(1):2–4.Google Scholar

North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. 1991;325:445–453.Google ScholarGoogle Scholar

European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351(9113):1371–1387.Google Scholar

Charles Picton Warlow. Prabook. Available at https://prabook.com/web/charles_picton.warlow/315427.Google Scholar

DeRango, P, Brown, MM, Didier, L, et al. Management of carotid stenosis in women: Consensus document. Neurology 2013;80(24):2258–2268.Google Scholar

Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421–1428.Google Scholar

Halliday, A, Mansfield, A, Marro, J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomised controlled trial. Lancet 2004;363(9420):1491–1502.Google Scholar

Benavente, O, Moher, D, Pham, B. Carotid endarterectomy for asymptomatic carotid stenosis: A meta-analysis. BMJ 1998;317:1477–1480.Google Scholar

Caplan, LR, Brott, TG. Of horse races, trials, meta-analyses, and carotid artery stenosis (Editorial). Arch. Neurol. 2011;68:157–159.Google Scholar

Brott, TG, Hobson, RW II, Howard, G, et al. CREST Investigators. Stenting vs endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 2010;363:11–23.Google Scholar

Bangalore, S, Kumar, S, Wetterslev, J, et al. Carotid artery stenting vs carotid endarterectomy: Meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch. Neurol. 2011;68(2):172–184.Google Scholar

Vitek, JJ, Raymon, BC, Oh, SJ. Innominate artery angioplasty. AJNR 1984;5:113–114.Google Scholar

Roubin, GS, Yadav, S, Iyer, SS, Vitek, J. Carotid stent-supported angioplasty: A neurovascular intervention to prevent stroke. Am. J. Cardiol. 1996 Aug 14;78(3A):8–12.Google Scholar

Brooks, WH, McClure, RR, Jones, MR, et al. Carotid angioplasty and stenting versus carotid endarterectomy: Randomized trial in a community hospital. J. Am. Coll. Cardiol. 2001;38:1589–1595.Google Scholar

Yadav, JS, Wholey, MH, Kuntz, RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. 2004;351:1493–1501.Google Scholar

Roubin, GS, New, G, Iyer, SS, Vitek, JJ, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: A 5-year prospective analysis. Circulation 2001;103(4):532–537.Google Scholar

Ederle, J, Bonati, LH, Dobson, J, et al. CAVATAS Investigators. Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): Long-term follow-up of a randomised trial. Lancet Neurol. 2009;8(10):898–907.Google Scholar

Brott, TG, Hobson, RW II, Howard, G, Roubin, GS, et al. CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 2010;363(1):11–23.Google Scholar

Caplan, LR, Brott, TG. Of horse races, trials, meta-analyses, and carotid artery stenosis (Editorial). Arch. Neurol. 2011;68:157–159.Google Scholar

Sirignano, P, Stabile, E, Mansour, W, et al. 1-month results from a prospective experience on CAS using CGuard stent system: The IRONGUARD 2 study. JACC Cardiovasc. Interv. 2020;13(18):2170–2177.Google Scholar

Lal, BK, Meschia, JF, Brott, TG. Clinical need, design, and goals for the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis trial. Semin. Vasc. Surg. 2017;30(1):2–7. Epub April 27, 2017.Google Scholar

Interventional treatment of aneurysms is discussed in Chapter 57, interventional treatment of AVMs in Chapter 59, and clot extraction in Chapter 56.Google Scholar

Higashida, RT, Myers, PM, IIIConnors, JJ, et al. Intracranial angioplasty and stenting for cerebral atherosclerosis: A position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. AJNR Am. J. Neuroradiol. 2005;26:2323–2327.Google Scholar

Connors, JJ III, Wojak, JC. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: Evolution of technique and short-term results. J. Neurosurgery 1999;91:415–423.Google Scholar

Feldman, RL, Trigg, L, Gaudier, J, Galat, J. Use of coroanry Palmaz-Schatz stent in the percutaneous treatment of an intracranial carotid artery stenosis. Cathet. Cardiovasc. Diagn. 1996;38:316–319.Google Scholar

Leung, TW, Wabnitz, AM, Miao, Z, Chimowitz, M. Agioplasty and stenting. In Kim, J, Caplan, LR, Wong, KS (eds.), Intracranial Atherosclerosis: Pathophysiology, Diagnosis and Treatment. Front. Neurol. Neurosci. Basel: Karger, 2016, vol. 40, pp. 152–163.Google Scholar

Chimowitz, MI, Lynn, MJ, Derdeyn, CP, et al. for the SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N. Engl. J. Med. 2011;365(11):993–1003.Google Scholar

Chimowitz, MI, Kokkinos, J, Strong, J, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488–1493.Google ScholarGoogle Scholar

Derdeyn, CP, Chimowitz, MI, Lynn, MJ, et al. for the for the SAMMPRIS Trial Investigators. Aggressive medical treatment with or without stenting in high risk patients with intracranial arterial stenosis (SAMMPRIS): The final trial results. Lancet 2014;383:333–341.Google Scholar

Zaidat, OO, Fitzsimmons, BF, Woodward, BK, for the VISSIT Trial Investigators. Effect of a balloon expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: The VISSIT randomized clinical trial. JAMA 2015;313:1240–1248.Google Scholar

Alexander, M.J., Zauner, A, Chaloupka, JC, et al. WEAVE Trial: Final results in 152 on-label patients. Stroke 2019;50(4):889–894.Google Scholar

Sussman, BJ, Fitch, TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J. Am. Med. Assoc. 1958;167:1705–1709.Google Scholar

Zeumer, H, Hacke, W, Ringelstein, EB. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR Am. J. Neuroradiol. 1983;4:401–404.Google Scholar

Zeumer, H, Hündgen, R, Ferbert, A, Ringelstein, EB. Local intraarterial fibrinolytic therapy in inaccessible internal carotid occlusion. Neuroradiology 1984;26:315–317.Google Scholar

Mori, E, Tabuchi, M, Yoshida, T, Yamadori, A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802–812.Google Scholar

Hacke, W, Zeumer, H, Ferbert, A, Brückmann, H, del Zoppo, GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216–1222.Google Scholar

del Zoppo, GJd, Higashida, RT, Furlan, AJ. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4–11.Google Scholar

Furlan, A, Higashida, R, Wechsler, L, Gent, M, Rowley, H, Kase, C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999;282:2003–2011.Google Scholar

Ogawa, A, Mori, E, Minematsu, K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke 2007;38:2633–2639.Google Scholar

Lewandowski, CA, Frankel, M, Tomsick, TA, et al. Combined intravenous and intra-arterial r-tPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) bridging trial. Stroke 1999;30:2598–2605.Google ScholarGoogle ScholarGoogle Scholar

Broderick, JP, Palesch, YY, Demchuk, AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 2013;368:893–903.Google ScholarGoogle ScholarGoogle Scholar

Nogueira, RG, Schwamm, LH, Hirsch, JA. Endovascular approaches to acute stroke, part 1: Drugs, devices, and data. AJNR Am. J. Neuroradiol. 2009;30:649–661.Google Scholar

Smith, WS, Sung, G, Saver, J, Budzik, R, Duckwiler, G, Liebeskind, DS, et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 2008;39:1205–1212.Google Scholar

The Penumbra Pivotal Stroke Trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009;40:2761–2768.Google Scholar

Castaño, C, Dorado, L, Guerrero, C, et al. Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: A pilot study. Stroke 2010;41:1836–1840.Google Scholar

Roth, C, Papanagiotou, P, Behnke, S, et al. Stent-assisted mechanical recanalization for treatment of acute intracerebral artery occlusions. Stroke 2010;41:2559–2567.Google Scholar

Saver, JL, Jahan, R, Levy, EI, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241–1249.Google ScholarGoogle Scholar

Examples include Goyal, M, Demchuk, AM, Menon, BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015;372:1019–1030.Google ScholarGoogle ScholarGoogle Scholar

Berkhemer, OA, Fransen, PS, Beumer, D, et al. for the MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015;372:11–20.Google Scholar

Goyal, M, Demchuk, AM, Menon, BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015;372:1019–1030.Google Scholar

Saver, JL, Goyal, M, Bonafe, A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. T-PA alone in stroke. N. Engl. J. Med. 2015;372:2285–2295.Google Scholar

Jovin, TG, Chamorro, A, Cobo, E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. 2015;372:2296–2306.Google Scholar